# Fluticasone + Vilanterol

## Relvar Ellipta 92/22mcg inhalation powder

##### 

| TAH Drug Code      | [ERELV](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ERELV)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Asthma: Treatment of asthma in patients >=18 years. Chronic obstructive pulmonary disease: Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema; to reduce exacerbations of COPD in patients with a history of exacerbations Fluticasone 100 mcg/vilanterol 25 mcg is the only strength indicated for the treatment of COPD.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Dosing             | One inhalation of Relvar Ellipta 92/22 micrograms once daily. (maximum dose: 1 inhalation/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Hypersensitivity to fluticasone, vilanterol or any component of the formulation; severe hypersensitivity to milk proteins; primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Adverse Effects    | 1% to 10%: Cardiovascular: Hypertension (>3%), peripheral edema (>3%), extrasystoles (>2%), supraventricular extrasystole (>2%), ventricular premature contractions (>2%) Central nervous system: Headache (5% to 8%) Gastrointestinal: Oropharyngeal candidiasis (2% to 5%), diarrhea (>3%), upper abdominal pain (>2%) Infection: Influenza (>3%) Neuromuscular & skeletal: Arthralgia (2% to >3%), back pain (2% to >3%), bone fracture (2%) Respiratory: Nasopharyngitis (6% to 10%), upper respiratory tract infection (>2% to 7%), pneumonia (2% to 7%), oropharyngeal pain (2% to ?3%), pharyngitis (2% to ?3%), chronic obstructive pulmonary disease (?3%), cough (1% to 3%), sinusitis (1% to 3%), bronchitis (3%), acute sinusitis (2%), allergic rhinitis (2%), rhinitis (2%), viral respiratory tract infection (2%), voice disorder (2%) Miscellaneous: Fever (2% to 3%) <1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, cataract, glaucoma, hypersensitivity reaction, muscle spasm, nervousness, palpitations, paradoxical bronchospasm, skin rash, tachycardia, tremor, urticaria |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

